Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Exousia Bio (LMMY) Shares Outstanding (Weighted Average) (2022 - 2025)

Lamy (LMMY) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 115.57% to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.8 million through Nov 2025, up 115.57% year-over-year, with the annual reading at $7.8 million for FY2025, 0.0% changed from the prior year.
  • Shares Outstanding (Weighted Average) hit $16.8 million in Q4 2025 for Lamy, up from $7.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $16.8 million in Q4 2025 to a low of $5.0 million in Q3 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $7.6 million across 4 years, with a median of $7.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): changed 0.0% in 2024 and later surged 115.57% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $5.0 million in 2022, then skyrocketed by 40.0% to $7.0 million in 2023, then increased by 11.1% to $7.8 million in 2024, then soared by 115.57% to $16.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for LMMY at $16.8 million in Q4 2025, $7.8 million in Q3 2025, and $7.8 million in Q2 2025.